Abstract
Evolution of Carbohydrate Antigen 19-9 Levels during Neoadjuvant Treatment Can Predict Resectability and Survival in Borderline Resectable Pancreatic Adenocarcinoma
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: HPB : the official journal of the International Hepato Pancreato Biliary Association
Paper Title
Journal
Date
